The Thoracic Oncology Program (TOP) team is committed to advancing the use of immunotherapy to treat thoracic malignancies. This Fund supports the team in their clinical research and treatment efforts, bringing them closer to understanding the mechanisms, including acquired resistances and successes, of molecularly targeted therapies and immunotherapies.
